Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system has been shown to have superior absorption compared to leading ethyl ester (EE) or reconstituted triglyceride (rTG) fish oil brands. IHN's Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada.
IHN's Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system has been shown to have superior absorption compared to leading ethyl ester (EE) or reconstituted triglyceride (rTG) fish oil brands. The benefits of omega-3 fatty acids as a dietary therapy are extremely well studied and documented. Clear indications include, but are not limited to: cellular antioxidant and anti-inflammatory properties. Clinical expertise, documented evidence, and patient compliance/value are three crucial key factors in selecting the appropriate omega-3 fatty acid product. Most often, patient compliance depends solely on their individual consumption experience. Incomplete digestion of an omega-3 product resulting in a repeat (fishy burp) is a common complaint and a major factor in poor compliance with fish oil supplementation. Enhanced Ω3 was designed with both clinicians and patients in mind; the natural emulsification of Enhanced Ω3 monoglyceride fish oil bypasses the digestive tract and facilitates its absorption into the body. Clinically, Enhanced O3 has demonstrated high absorption properties even in the absence of digestive enzymes, an absorption rate 3 times higher than standard ethyl ester or reconstituted triglyceride fish oils, and allows for increased patient compliance thanks to modest daily requirements.
Adults: 1 to 2 capsules per day.
Medicinal ingredients per softgel:
Fish oil 805 mg including: EPA 320 mg, DHA 185 mg
Non-medicinal ingredients: Softgel (bovine gelatin, glycerin, purified water), sunflower oil, lemon essential oil, natural mixed tocopherols.
